MedTrace Logo

Metformin in Chronic Obstructive Pulmonary Disease

NCT01247870 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2015-05-07

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of a tablet medication, called metformin, in flare-ups (exacerbations) of chronic obstructive pulmonary disease. The investigators believe that metformin may effectively control the blood sugar level during COPD exacerbations. This is important because there is evidence that a high blood sugar level during exacerbations may be linked with a worse prognosis. The investigators also think that metformin may have other potentially useful effects on inflammation, antioxidant levels, the effectiveness of steroid treatment, and recovery.

Conditions

Interventions

DRUG

Metformin

Metformin 1 g twice daily for 28-35 days

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Medical Research Council

    collaborator OTHER_GOV

  • British Lung Foundation

    collaborator OTHER

  • St George's, University of London

    lead OTHER

Principal Investigators

  • Emma H Baker, MBChB PhD · St George's, University of London

  • Andrew W Hitchings, BSc MBBS · St George's Healthcare NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2014-03-31
Completion
2014-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01247870 on ClinicalTrials.gov